Company: HABSONS Jobsup Limited
Qualification: Master OF Business Administration (M.B.A)
Experience: 10 to 12
Salary: 4.50 to 5.00
location: Delhi
Ref: 24828362
Summary: Business Development,OUTSOURCING,Recruitment,Healthcare,Para Medical,Recruitment Consultancy

Company: Talent Corner Hr Services Private Limited
Experience: 6 to 11
location: Mumbai, Pune
Ref: 24788408
Summary: Job Description : Job Description Drive PP Sales through OP partners & PP Re-sellers in the designated territory to achieve PP business revenue & Unit Plans in accordance to the business plans Meets....

Company: P & I Management Consultants
Experience: 6 to 9
location: India, Ludhiana
Ref: 24657059
Summary: Job Description: Job Description Graduate with over 6 years experience in Sales and Counseling for Immigration to Canada and arranging Study Visa for Canada. Must be expert in Agent-Networking for Immigration Services, ....

Company: Confidential
Experience: 0 to 3
Salary: 1.80 to 2.40
location: Mumbai, Mumbai City, Navi Mumbai
Ref: 18534064
Summary: The Role will include selling Web Solutions such as Google Suite, Google Adwords Management, Cloud based Solutions, Corporate Web-Email Hosting Solutions, Web Design and Development, ....

Company: Hetang Bhavshar(Proprietor of HB Staffing Services
Experience: 5 to 12
Salary: 5.00 to 15.00
location: Ahmedabad
Ref: 24828929
Summary: We have Requirement For Python Developer Team leader

Company: Indscope
Experience: 2 to 4
Salary: 3.00 to 4.20
location: Bengaluru / Bangalore
Ref: 24828923
Summary: 2-3 years of iOS application development, with extensive use of Obj-C (or Swift) IO, collections, algorithms, and well-known application frameworks

Company: Microchip Technology India Private Limited
Experience: 2 to 5
location: Bengaluru / Bangalore
Ref: 24828664
Summary: Job Description Early-career Full Stack Development Engineer opening based in Bangalore, India to be a key contributor in the development effort of our next generation common automated test framework and ....

Company: Microchip Technology India Private Limited
Experience: 4 to 5
location: India
Ref: 24828663
Summary: Job Description r Responsibilities * DCS Embedded System Test Automation Team * Key contributor in the Quality Assurance effort of MCHP DCS storage products * Design and develop common automation framework....

Company: 2COMS Consulting Private Limited
Experience: 1 to 3
location: Mumbai, Navi Mumbai
Ref: 24634989
Summary: Hello All, Leading MNC hiring for RPA Developer & DOT NET Developer PROFILE@ Mumbai Salary- UPTO 40-45 K CTC + PF+ESIC Both side CAB facilites. 5 days of working **Rotational SHIFT JOB ** ....

Company: 2COMS Consulting Private Limited
Experience: 1 to 3
location: Mumbai
Ref: 24588608
Summary: HI GREETINGS FROM 2COMS!!!!!!! LEADING MNC HIRING WEB DEVELOPERS @ VIKHROLI Graduates with 1+ years Exp as Frontend Web Developer Skills FRESHERS ARE NOT ELIGIBLE required: HTML CSS, Javascript & Jquery. Wordpress/AEM....

Company: Confidential
Qualification: Aviation, Bachelor of Arts (B.A), Bachelor of Architecture (B.Arch), Bachelor of Business Administration (B.B.A), Bachelor Of Computer Application (B.C.A), Bachelor of Commerce (B.Com), Bachelor Of Technology (B.Tech/B.E), Bachelor of Education (B.Ed), Bachelor in Hotel Management....

Company: ILabz Technology LLP
Experience: 3 to 8
location: Chennai
Ref: 24481861
Summary: Java, Spring, Hibernate, Spring boot

Company: Resource Access Management Solutions Private Limited
Experience: 6 to 8
location: India
Ref: 24424286
Summary: Company: Global Investment Bank Experience: 6 - 8 Yrs Job Location: Bangalore Key Skills: Java, SQL, Multi-threading Must Have Skills: Java, SQL, Multi-threading INDUSTRY Banking & Financial ROLE Java....

Company: Resource Access Management Solutions Private Limited
Experience: 10 to 12
location: India
Ref: 24423080
Summary: Company - A Global Investment Bank Experience: 10 - 12 Years Education: Any UG / PG ROLES AND RESPONSIBILITIES JOB PURPOSE To deliver the quality talent & leadership development in the Finance Shared....

Company: Resource Access Management Solutions Private Limited
Experience: 0 to 50
location: Chennai
Ref: 24410443
Summary: Company: Leading IT Company Experience: 3 - 6 Yrs Job Location: Chennai Key Skills: Java Scala Must Have Skills: Slick Microservices Mockito Docker INDUSTRY IT-Software / Software Services ....

Company: SP Staffing Services Private Limited
Qualification: Other
Experience: 1 to 5
Salary: 3.50 to 6.10
location: Chennai
Ref: 24374534
Summary: Immediate Hiring For Python Developer

Company: Job Store Consulting
Experience: 2 to 10
location: Coimbatore
Ref: 24239466
Summary: Job Description : Qualifications and Experience: - Salesforce Developer Certification - Strong experience in Lightning - Lightning Flows, Apex Class callouts, Lightning Web Components - Strong experience in Salesforce....

Company: Job Store Consulting
Experience: 2 to 5
location: Chennai
Ref: 24038750
Summary: Job Description : Openings for Java Developer Mid/Senior Full Stack Java Developer Experience: 2+ years Skills: Java, Spring, Hibernate, MySQL, HTML/CSS3/Javascript Salary up to4.5 LPA For more details Contact: HR Meera @8489435355 /....

On Friday, the Reserve Bank of India (RBI) received 4.8 times the notified bids at the auction of the new 10-year government security paper (G-Sec). These are scheduled to mature in 2030 and carry a coupon rate (interest) of 5.79 percent,

On Friday, the Reserve Bank of India (RBI) received 4.8 times the notified bids at the auction of the new 10-year government security paper (G-Sec). These are scheduled to mature in 2030 and carry a coupon rate (interest) of 5.79 percent,

The vaccine will be developed using the virus strain isolated at the ICMR#39;s National Institute of Virology (NIV), Pune, a statement said.

"National Institute of Virology, Pune, has successfully developed the 1st indigenous anti-SARS-CoV-2 human IgG ELISA test kit for antibody detection of COVID-19," the minister said in one of a series of tweets. "This robust test will play a critical role in surveillance of proportion of population exposed to SARSCoV2 infection," he said.

1. Vitamin D-deficient Patients Twice As Likely To Develop Severe COVID-19 Symptoms  Green Prophet
2. Researchers Have Discovered a Strong Correlation Between Severe Vitamin D Deficiency and COVID-19 Mortality Rates  Technology Networks
3. If your body has low levels of this, you have a higher chance of dying from COVID-19  Ladders
4. New study links low vitamin D levels with high COVID-19 death rate  Gulf News
5. Vitamin D is associated with a low COVID-19 death rate  Tech Explorist
6. View Full coverage on Google News

1. Elon Musk threatens to 'exit California' over virus restrictions  9News
2. Elon Musk says Tesla will move headquarters from California 'immediately' over coronavirus restrictions  ABC News
3. Elon Musk threatens to relocate Tesla  NEWS.com.au
4. Elon Musk threatens to close Fremont plant and sever ties with California  KTVU San Francisco
5. Tesla’s stock could see new peaks thanks to these 3 catalysts  MarketWatch
6. View Full coverage on Google News

Elon Musk wil Teslafabriek verhuizen uit protest tegen lockdown  De TijdHele verhaal bekijken via Google Nieuws

DENVER (February 19, 2020) — Today, the U.S.

He may have just welcomed a new baby, but Elon Musk can still act like one himself.

He may have just welcomed a new baby, but Elon Musk can still act like one himself.

The company's CEO tweeted Saturday that the automaker is seeking legal action against Alameda County. The billionaire executive has been sharply critical of shelter-in-place orders in recent weeks.

Saturday Elon Musk announced he'd "immediately" relocate Tesla's headquarters and "future programs" to Texas and Nevada, reports Ars Technica. While California lifted its restrictions on manufacturers and businesses, the county of Alameda (where Tesla is located) says the company's manufacturing plant does not yet meet the county's requirements for safely reopening. "Frankly, this is the final straw," Musk tweeted. Musk also announced his intent to file a lawsuit against Alameda County officials "immediately," adding, "The unelected & ignorant 'Interim Health Officer' of Alameda is acting contrary to the Governor, the President, our Constitutional freedoms & just plain common sense!" Musk also encouraged Tesla shareholders to file a class-action suit against the county. The latest back-and-forth between Tesla and Alameda County officials began on Thursday, when a memo sent to Tesla employees indicated that its Fremont plant would reopen "at 30% our normal headcount per shift," as reported by TechCrunch. Alameda officials responded on Friday with a firm reminder that the county's stay-in-place order would remain in effect for Tesla, and all other "non-essential" operations in the county, until May 31, with the exception of "basic" operations... "We have informed Tesla of all of the conditions that must exist for phasing in the safe reopening of various sectors of the economy and the community. Tesla has been informed that they do not meet those criteria and must not reopen. We welcome Tesla's proactive work on a reopening plan so that once they fit the criteria to reopen, they can do so in a way that protects their employees and the community at large."

Read more of this story at Slashdot.

Tesla boss Elon Musk has threatened to pull the firm's headquarters and only US car factory out of California after local officials stopped the company from reopening the electric vehicle plant.

In a tweet Saturday morning, Tesla's chief executive said it would file a lawsuit against county officials over not being able to run its factory.

β-1,3-d-Glucan is a ubiquitous glucose polymer produced by plants, bacteria, and most fungi. It has been used as a diagnostic tool in patients with invasive mycoses via a highly-sensitive reagent consisting of the blood coagulation system of horseshoe crab. However, no method is currently available for measuring β-1,6-glucan, another primary β-glucan structure of fungal polysaccharides. Herein, we describe the development of an economical and highly-sensitive and specific assay for β-1,6-glucan using a modified recombinant endo-β-1,6-glucanase having diminished glucan hydrolase activity. The purified β-1,6-glucanase derivative bound to the β-1,6-glucan pustulan with a KD of 16.4 nm. We validated the specificity of this β-1,6-glucan probe by demonstrating its ability to detect cell wall β-1,6-glucan from both yeast and hyphal forms of the opportunistic fungal pathogen Candida albicans, without any detectable binding to glucan lacking the long β-1,6-glucan branch. We developed a sandwich ELISA-like assay with a low limit of quantification for pustulan (1.5 pg/ml), and we successfully employed this assay in the quantification of extracellular β-1,6-glucan released by >250 patient-derived strains of different Candida species (including Candida auris) in culture supernatant in vitro. We also used this assay to measure β-1,6-glucan in vivo in the serum and in several organs in a mouse model of systemic candidiasis. Our work describes a reliable method for β-1,6-glucan detection, which may prove useful for the diagnosis of invasive fungal infections.

Multidrug resistance (MDR) in cancer arises from cross-resistance to structurally- and functionally-divergent chemotherapeutic drugs. In particular, MDR is characterized by increased expression and activity of ATP-binding cassette (ABC) superfamily transporters. Sphingolipids are substrates of ABC proteins in cell signaling, membrane biosynthesis, and inflammation, for example, and their products can favor cancer progression. Glucosylceramide (GlcCer) is a ubiquitous glycosphingolipid (GSL) generated by glucosylceramide synthase, a key regulatory enzyme encoded by the UDP-glucose ceramide glucosyltransferase (UGCG) gene. Stressed cells increase de novo biosynthesis of ceramides, which return to sub-toxic levels after UGCG mediates incorporation into GlcCer. Given that cancer cells seem to mobilize UGCG and have increased GSL content for ceramide clearance, which ultimately contributes to chemotherapy failure, here we investigated how inhibition of GSL biosynthesis affects the MDR phenotype of chronic myeloid leukemias. We found that MDR is associated with higher UGCG expression and with a complex GSL profile. UGCG inhibition with the ceramide analog d-threo-1-(3,4,-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (EtDO-P4) greatly reduced GSL and monosialotetrahexosylganglioside levels, and co-treatment with standard chemotherapeutics sensitized cells to mitochondrial membrane potential loss and apoptosis. ABC subfamily B member 1 (ABCB1) expression was reduced, and ABCC-mediated efflux activity was modulated by competition with nonglycosylated ceramides. Consistently, inhibition of ABCC-mediated transport reduced the efflux of exogenous C6-ceramide. Overall, UGCG inhibition impaired the malignant glycophenotype of MDR leukemias, which typically overcomes drug resistance through distinct mechanisms. This work sheds light on the involvement of GSL in chemotherapy failure, and its findings suggest that targeted GSL modulation could help manage MDR leukemias.

The report examines U.S. immigration and international development policies, which have unique objectives and respond to distinct political and administrative constraints, and points out that international development has never been a U.S. immigration policy objective; nonetheless, it is an unintended consequence.

Migration and development have emerged as a pressing policy priority on the global agenda. This report identifies critical lessons from the past decade of policy experimentation and offers recommendations for migration and development policy.

This report focuses on the development of children of Black immigrants in the United States, comparing against the outcomes for their peers in native-born and other immigrant families. It also compares these U.S. children to those in the United Kingdom, where there is a large Black immigrant population but a notably different policy context of reception.

This edited volume examines the development impact of diasporas in six critical areas: entrepreneurship, capital markets, "nostalgia" trade and "heritage" tourism, philanthropy, volunteerism, and advocacy.

Ce manuel pratique et simple d’utilisation à l’usage des décideurs et des praticiens fait le point des mesures les plus récentes prises par les pouvoirs publics en direction des diasporas. La question qui se pose aux responsables politiques n’est pas tant de savoir si les diasporas peuvent être utiles à leur pays d’origine, mais comment elles le sont et quels types de politiques et de programmes publics sont à même de favoriser ces relations.

This practical handbook highlights policies and programs that can magnify the resources, both human and financial, that emigrants and their descendants contribute to development. It gives concrete examples of policies and programs that have been effective, and pulls out both useful lessons and common challenges associated with the topics at hand.

This edited volume develops a pragmatic approach to the engagement of highly skilled members of the diaspora for the benefit of their countries of origin. The book, edited by a World Bank senior economist, is based on empirical work in middle-income and high-income economies.

This interactive language access webinar, one in a series offered by the Migration Policy Institute's National Center on Immigrant Integration Policy, examines how New York and Illinois have broken down some of these barriers to proactively engage LEP communities to obtain workforce services.

This webinar examines how New York and Illinois have proactively engaged Limited English Proficient (LEP) communities to obtain workforce services.

Researchers at MIT have developed a new method of electrically stimulating deep brain tissues without opening the skull

Since 1997, more than 100,000 Parkinson’s Disease patients have been treated with deep brain stimulation (DBS), a surgical technique that involves the implantation of ultra-thin wire electrodes. The implanted device, sometimes referred to as a ‘brain pacemaker’, delivers electrical pulses to a structure called the subthalamic nucleus, located near the centre of the brain, and effectively alleviates many of the physical symptoms of the disease, such as tremor, muscle rigidity, and slowed movements.

DBS is generally safe but, like any surgical procedure, comes with some risks. First and foremost, it is highly invasive, requiring small holes to be drilled in the patient’s skull, through which the electrodes are inserted. Potential complications of this include infection, stroke, and bleeding on the brain. The electrodes, which are implanted for long periods of time, sometimes move out of place; they can also cause swelling at the implantation site; and the wire connecting them to the battery, typically placed under the skin of the chest, can erode, all of which require additional surgical procedures.

Related: Blowing up the brain to reveal its finer details

Related: Traces of memory in a dish | Mo Costandi

Part of a series exploring recommendations likely to be addressed by the new National Integration Plan, this webinar, with perspectives from MPI, the WE Global Network, and Lutheran Immigrant and Refugee Services, examines the role of economic development initiatives and refugee resettlement programs/infrastructure in immigrant integration. 

This webinar, with perspectives from MPI, the WE Global Network, and Lutheran Immigrant and Refugee Service, examines the role of economic development initiatives and refugee resettlement programs/infrastructure in immigrant integration.

Tesla CEO Elon Musk threatened Saturday to pull the company's factory and headquarters out of California and sued local officials who have stopped the company from reopening its electric vehicle factory.

1. India's research body partners with vaccine manufacturing company to develop indigenous vaccine for COVID-19  China.org.cn
2. India to develop ‘fully indigenous’ Covid vaccine as ICMR partners with Bharat Biotech  ThePrint
3. ICMR teams up with Bharat Biotech to develop Covid-19 vaccine  Times of India
4. ICMR partners with Bharat Biotech to develop an indigenous coronavirus vaccine  Times Now
5. ICMR joins with Hyderabad firm to develop COVID-19 vaccine  Northeast Now
6. View Full coverage on Google News